The FDA has cleared Lineage Cell Therapeutics' investigational new drug (IND) amendment for OPC1 cell therapy transplant for treating patients with spinal cord injury (SCI), allowing the company to initiate a study evaluating a novel delivery device for the therapy in patients with subacute and chronic SCI. Lineage Cell has initiated activities to open its first clinical site in the new study evaluating the novel delivery device, termed DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device. The company expects to be able to open the initial in the second quarter of 2024, following trial preparations and a grant submission to the California Institute for Regenerative Medicine in the first quarter of the year.